

Resource Summary Report

Generated by [dkNET](#) on Aug 13, 2026

PerCP anti-mouse/human CD44

RRID:AB_10645506

Type: Antibody

Proper Citation

BioLegend Cat# 103036, RRID:AB_10645506

Antibody Information

URL: http://antibodyregistry.org/AB_10645506

Proper Citation: BioLegend Cat# 103036, RRID:AB_10645506

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_10645506

Vendor: BioLegend

Catalog Number: 103036

Alternative Catalog Numbers: 103035

Record Creation Time: 20250820T064500+0000

Record Last Update: 20250821T005031+0000

Ratings and Alerts

No rating or validation information has been found for PerCP anti-mouse/human CD44.

No alerts have been found for PerCP anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Salazar-Cavazos E, et al. (2026) Stochasticity in cancer immunotherapy stems from rare but functionally critical Spark T cells. *Cell*, 189(4), 1074.

Pei Z, et al. (2026) STAT3 interference-driven nanomodulators reverse lipid metabolism-associated chemoresistance and potentiate metalloimmunotherapy in breast cancer. *Cell reports. Medicine*, 7(6), 102844.

Wells RC, et al. (2025) Dual targeting of transferrin receptor and CD98hc enhances brain exposure of large molecules. *Cell reports*, 44(8), 116038.

Fan Q, et al. (2025) Hepatic Lamp2a deficiency promotes inflammation of murine autoimmune cholangitis via affecting bile acid metabolism. *iScience*, 28(2), 111804.

Kondo T, et al. (2025) Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. *Cell*, 188(9), 2372.

Abdullah L, et al. (2025) The endogenous antigen-specific CD8+ T cell repertoire is composed of unbiased and biased clonotypes with differential fate commitments. *Immunity*, 58(3), 601.

Archer D, et al. (2025) A secondary metabolite of *Limosilactobacillus reuteri* R2lc drives strain-specific pathology in a spontaneous mouse model of multiple sclerosis. *Cell reports*, 44(3), 115321.

Oami T, et al. (2024) Claudin-2 upregulation enhances intestinal permeability, immune activation, dysbiosis, and mortality in sepsis. *Proceedings of the National Academy of Sciences of the United States of America*, 121(10), e2217877121.

Wu N, et al. (2024) MerTK+ macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation. *Science advances*, 10(40), eado8366.

West EE, et al. (2023) Loss of CD4+ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection. *Immunity*, 56(9), 2036.

Zander R, et al. (2022) Tfh-cell-derived interleukin 21 sustains effector CD8+ T cell responses during chronic viral infection. *Immunity*, 55(3), 475.